New Guidelines Back Hormone Therapy for Menopause Symptoms
Left 33%
Center 67%
Right 0%
1 left · 2 center · 0 right
What happened
The American College of Obstetricians and Gynecologists (ACOG), the leading U.S. OB-GYN professional organization, released new clinical guidance on treating common menopause and perimenopause symptoms—the first change in more than a decade to its advice on hormone therapy. ACOG now recommends hormone replacement therapy as first-line treatment for many women with vasomotor symptoms such as hot flashes and night sweats, stating that benefits outweigh harms for eligible patients. Therapy should generally begin before age 60 or within 10 years of menopause onset. Women with a history of blood clots, stroke, liver disease, or personal history of breast cancer are advised not to use these therapies. Delivery options include pills, patches, sprays, gels, vaginal rings, and low-dose vaginal estrogen.
Sourcing check · Fully on the record · 3 articles
2 of 2 articles cite a named source for the story. It was on the record from the first report.
What these terms mean and how they're counted
- On the record · names a source 2 of 2
- On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: American College of Obstetricians and Gynecologists and Dr. Kameelah Phillips
- Primary evidence · cites a document or data 1 of 2
- Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: ACOG guidance, 2002 study
- Credits another outlet 0 of 2
- The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
- Unnamed sources 0 of 2
- The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
- How it developed
- When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 15, 15:00 UTC by New York Times, naming its source. First document the next day, from CBS News (ACOG guidance).
- Not counted 1
- Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
BLINDSPOT.
Only left-leaning outlets are covering this story
— the other side's media is silent.
Omitted — what each side leaves out
Unpacked
Right-leaning outlets had not covered the new menopause guidelines as of publication, leaving those readers without the core finding left-leaning coverage reports. Left-leaning coverage says the American College of Obstetricians and Gynecologists found that the "benefits of the treatment outweigh the harms" for many women. Left-leaning coverage does not split on that point, but it also does not mention older research that once tied hormones to a higher risk of breast cancer. That account does not include the warning that women with a history of blood clots, stroke, or liver disease should not use hormone therapy. A reader of the silent side therefore misses both that shift and the further claim that hormone replacement therapy is now the first line for hot flashes and night sweats. The same reader would not see the advice to start treatment before age 60.
How many years do the new guidelines say a woman should remain on hormone therapy after starting it?
Bottom line
The New York Times carried ACOG's line that hormone therapy's benefits outweigh the harms for many women; right-leaning outlets have not reported the new menopause guidelines at all.
The receipts — 5 facts one side's coverage lacks
- ACOG said the benefits of hormone therapy outweigh the harms for many women
- ACOG is changing its hormone-therapy advice for the first time in more than a decade
- Women with a personal history of breast cancer should avoid hormone replacement therapy
- A 2002 long-term study raised concerns that hormone use could be linked to an increase in breast cancer
- ACOG says women should begin hormone replacement therapy within 10 years of starting menopause
The Left View
The New York Times reported that ACOG said the benefits of hormone therapy outweigh the harms for many women. CBS News covered the guidelines in greater detail, quoting menopause specialist Dr. Kameelah Phillips that hormone replacement therapy is now first-line for hot flashes, night sweats, and sleep issues, and that earlier informal advice (antidepressants, exercise, alcohol) was not helpful. CBS noted eligibility limits, the 2002 long-term women’s health study that raised breast-cancer concerns (focused on older patients who started therapy about a decade after menopause), and newer research indicating age and dosing can make treatment safer for many patients. ACOG said menopause is a normal stage of life but women need not suffer without help; those ineligible may have non-hormonal options after consulting a specialist.
Our Take (balanced)
The story is substantive: it rests on named actors (ACOG), an official change in clinical guidance, specific eligibility rules, and checkable claims about prior versus newer research—not one party’s uncorroborated word. The guideline shift and stated contraindications are established; remaining medical debate (long-term risk profiles, individual dosing) is scientific, not alleged misconduct. No right-leaning outlet has reported this. Watch for the full ACOG guidance document, statements from other medical societies, and any follow-on studies or regulator commentary on hormone therapy safety and timing.
3 sources
More stories
The week's bottom lines, in your inbox
One email a week: the five stories that mattered and what they actually mean. Free.